Fluticasone Propionate Nasal Spray (FLONASE(R)) will be the first product marketed under this arrangement
MASON, Ohio, March 11 /PRNewswire/ -- Prasco Laboratories, announced today it has entered into a marketing and distribution agreement with GlaxoSmithKline (NYSE: GSK). FLONASE(R) (fluticasone propionate) Nasal Spray is the first product to be marketed under this agreement. Prasco, as GSK's agent and on GSK's behalf, will solicit orders for, and distribute Fluticasone Propionate Nasal Spray to all trade classes in the U.S. under a GSK/Prasco label.
"We are especially proud to have established this relationship with GlaxoSmithKline, a global leader in the research-based pharmaceutical industry," said Prasco Chief Executive Officer E. Thomas Arington. "We look forward to working with GSK to provide more choices for patients in the generics market."
"GlaxoSmithKline is always looking for opportunities to increase access to our medicines for patients," said Stan Hull, GlaxoSmithKline Senior Vice President, U.S. Pharmaceuticals. "The arrangement with Prasco, a known leader in the generics market, allows GSK to expand participation in the generic market in a new way."
Fluticasone Propionate Nasal Spray is AB-rated, therapeutically equivalent and substitutable for the brand FLONASE Nasal Spray. Fluticasone Propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.
FLONASE(R) is a registered trademark of Glaxo Group Limited, UK.
Prasco's mission is to provide both quality products and significant cost-savings to the consumer. Prasco's goal is to provide patients with brand sameness through Prasco Authorized Generics, which are brand-products sold under the Prasco private label. Prasco's executive team has extensive experience working within both the brand and generic industries. A centerpiece of the company's corporate capabilities is its sales/marketing and business development teams. Prasco's product line is currently sold through the major distribution channels, including chains, independent pharmacies, distributors, wholesalers, and managed care providers.
The company operates from a 160,000 sq. ft. administrative office and warehouse facility and has complete control over product distribution management systems--including DEA-approved facilities for Schedule II-V controlled drug products.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com
|SOURCE Prasco Laboratories|
Copyright©2009 PR Newswire.
All rights reserved